Cargando…
How innovation can be defined, evaluated and rewarded in health technology assessment
BACKGROUND: What constitutes innovation in health technologies can be defined and measured in a number of ways and it has been widely researched and published about. However, while many countries mention it as a criterion for pricing or reimbursement of health technologies, countries differ widely i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725438/ https://www.ncbi.nlm.nih.gov/pubmed/34981266 http://dx.doi.org/10.1186/s13561-021-00342-y |
_version_ | 1784626117214208000 |
---|---|
author | Rejon-Parrilla, Juan Carlos Espin, Jaime Epstein, David |
author_facet | Rejon-Parrilla, Juan Carlos Espin, Jaime Epstein, David |
author_sort | Rejon-Parrilla, Juan Carlos |
collection | PubMed |
description | BACKGROUND: What constitutes innovation in health technologies can be defined and measured in a number of ways and it has been widely researched and published about. However, while many countries mention it as a criterion for pricing or reimbursement of health technologies, countries differ widely in how they define and operationalise it. METHODS: We performed a literature review, using a snowballing search. In this paper, we explore how innovation has been defined in the literature in relation to health technology assessment. We also describe how a selection of countries (England, France, Italy, Spain and Japan) take account of innovation in their health technology assessment frameworks and explore the key methodologies that can capture it as a dimension of value in a new health technology. We propose a way of coming to, and incorporating into health technology assessment systems, a definition of innovation for health technologies that is independent of other dimensions of value that they already account for in their systems, such as clinical benefit. We use Spain as an illustrative example of how innovation might be operationalised as a criterion for decision making in health technology assessment. RESULTS: The countries analysed here can be divided into 2 groups with respect to how they define innovation. France, Japan and Italy use features such as severity, unmet need and therapeutic added value as indicators of the degree of innovation of a health technology, while England, Spain consider the degree of innovation as a separate and additional criterion from others. In the case of Spain, a notion of innovation might be constructed around concepts of `step-change’, `convenience’, `strength of evidence base’ and `impact on future research & development’. CONCLUSIONS: If innovation is to be used as operational criteria for adoption, pricing and reimbursement of health technologies, the concept must be clearly defined, and it ought to be independent from other value dimensions already captured in their health technology assessment systems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-021-00342-y. |
format | Online Article Text |
id | pubmed-8725438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-87254382022-01-06 How innovation can be defined, evaluated and rewarded in health technology assessment Rejon-Parrilla, Juan Carlos Espin, Jaime Epstein, David Health Econ Rev Review BACKGROUND: What constitutes innovation in health technologies can be defined and measured in a number of ways and it has been widely researched and published about. However, while many countries mention it as a criterion for pricing or reimbursement of health technologies, countries differ widely in how they define and operationalise it. METHODS: We performed a literature review, using a snowballing search. In this paper, we explore how innovation has been defined in the literature in relation to health technology assessment. We also describe how a selection of countries (England, France, Italy, Spain and Japan) take account of innovation in their health technology assessment frameworks and explore the key methodologies that can capture it as a dimension of value in a new health technology. We propose a way of coming to, and incorporating into health technology assessment systems, a definition of innovation for health technologies that is independent of other dimensions of value that they already account for in their systems, such as clinical benefit. We use Spain as an illustrative example of how innovation might be operationalised as a criterion for decision making in health technology assessment. RESULTS: The countries analysed here can be divided into 2 groups with respect to how they define innovation. France, Japan and Italy use features such as severity, unmet need and therapeutic added value as indicators of the degree of innovation of a health technology, while England, Spain consider the degree of innovation as a separate and additional criterion from others. In the case of Spain, a notion of innovation might be constructed around concepts of `step-change’, `convenience’, `strength of evidence base’ and `impact on future research & development’. CONCLUSIONS: If innovation is to be used as operational criteria for adoption, pricing and reimbursement of health technologies, the concept must be clearly defined, and it ought to be independent from other value dimensions already captured in their health technology assessment systems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-021-00342-y. Springer Berlin Heidelberg 2022-01-03 /pmc/articles/PMC8725438/ /pubmed/34981266 http://dx.doi.org/10.1186/s13561-021-00342-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Rejon-Parrilla, Juan Carlos Espin, Jaime Epstein, David How innovation can be defined, evaluated and rewarded in health technology assessment |
title | How innovation can be defined, evaluated and rewarded in health technology assessment |
title_full | How innovation can be defined, evaluated and rewarded in health technology assessment |
title_fullStr | How innovation can be defined, evaluated and rewarded in health technology assessment |
title_full_unstemmed | How innovation can be defined, evaluated and rewarded in health technology assessment |
title_short | How innovation can be defined, evaluated and rewarded in health technology assessment |
title_sort | how innovation can be defined, evaluated and rewarded in health technology assessment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725438/ https://www.ncbi.nlm.nih.gov/pubmed/34981266 http://dx.doi.org/10.1186/s13561-021-00342-y |
work_keys_str_mv | AT rejonparrillajuancarlos howinnovationcanbedefinedevaluatedandrewardedinhealthtechnologyassessment AT espinjaime howinnovationcanbedefinedevaluatedandrewardedinhealthtechnologyassessment AT epsteindavid howinnovationcanbedefinedevaluatedandrewardedinhealthtechnologyassessment |